fever; off label use; interchange of vaccine products; tinnitus; this is a spontaneous report received from a contactable reporter(s) (consumer or other non hcp) from the regulatory authority. regulatory number: gb-mhra-webcovid-202202170802402160-y1iuj. a patient (no qualifiers provided) received bnt162b2 (comirnaty), administration date 22jan2022 (lot number: fl9994) as dose 3 (booster), single for covid-19 immunisation. relevant medical history included: "suspected covid-19" (unspecified if ongoing), notes: unsure when symptoms started, unsure when symptoms stopped. the patient's concomitant medications were not reported. vaccination history included: covid-19 vaccine astrazeneca (dose 1), administration date: 12may2021, for covid-19 immunisation; covid-19 vaccine astrazeneca (dose 2), administration date: 12jul2021, for covid-19 immunisation. the following information was reported: off label use (medically significant) with onset 22jan2022, outcome "unknown", described as "off label use"; interchange of vaccine products (medically significant) with onset 22jan2022, outcome "unknown", described as "interchange of vaccine products"; tinnitus (medically significant) with onset 22jan2022, outcome "not recovered", described as "tinnitus"; pyrexia (medically significant), outcome "not recovered", described as "fever". the patient underwent the following laboratory tests and procedures: sars-cov-2 test: negative, notes: no - negative covid-19 test. additional information: patient reportedly got all common side effects fever etc. the next day after vaccine plus some tinnitus. tinnitus has now evolved into three (3) different types. patient has not tested positive for covid-19 since having the vaccine. patient is not enrolled in clinical trial. relevant investigations or tests were conducted by gp & audiologist (unspecified). no follow-up attempts are possible. no further information is expected